CASP3 and neoplasm: Further investigation of the tumor growth inhibitory action of nab-paclitaxel-based chemotherapy regimens and trametinib exhibited that trametinib significantly decreased ERK phosphorylation and concomitantly increased the expression of apoptosis-associated proteins cleaved caspase-3 and cleaved PARP-1 (Figure 5).